Achalasia cardia is a primary motility disorder of the esophagus, defined by lack of normal esophageal peristalsis along with inadequate relaxation of lower esophageal sphincter. The mainstay of management in achalasia includes pneumatic dilatation, Heller’s myotomy and peroral endoscopic myotomy (POEM). Pneumatic dilatation and Heller’s myotomy have gained maturity over several decades. The current best practice with regard to pneumatic dilatation is graded and on-demand dilatation in appropriately selected cases with type I and II achalasia. Laparoscopic Heller’s myotomy plus partial fundoplication is minimally invasive with reduced postoperative reflux and has virtually replaced open Heller’s myotomy with or without fundoplication. The subtyping of achalasia using high-resolution manometry bears prognostic significance and may help in choosing appropriate therapeutic modality in these patients. Since all the three modalities are effective for type I and II achalasia, the choice among these depends on the availability, expertise, and patient’s preferences. On the other hand, POEM is more effective than pneumatic dilatation and Heller’s myotomy and, therefore, preferred in type III achalasia. Although POEM is effective across the spectrum of esophageal motility disorders, the incidence of gastroesophageal reflux is high and needs to be considered while choosing among various options in these patients. In cases with failed POEM, redo POEM appears to be effective in alleviating symptoms.
of achalasia include pneumatic dilatation (PD), peroral endoscopic myotomy (POEM), and laparoscopic Heller’s myotomy (LHM).

In the following sections, we discuss the role of various modalities for the management of achalasia in the current era.

Classification of Esophageal Motility Disorders

Esophageal motility disorders are broadly divided into disorders of gastroesophageal junction (GEJ) outflow obstruction and disorders of peristalsis. Disorders of GEJ outflow obstruction include achalasia cardia and esophagogastric junction outflow obstruction (EGJOO), whereas peristaltic disorders without impairment of GEJ outflow are constituted by hypercontractile esophagus and distal esophageal spasm. This subdivision of esophageal motility disorders bears prognostic and therapeutic relevance. Therapeutic modalities like dilatation are mainly directed at GEJ and, therefore, relatively ineffective in spastic esophageal motility disorders, where spasms involving variable length of esophagus are involved in the genesis of symptoms. On the other hand, myotomy (especially endoscopic) can address the spastic segments of esophagus and is preferred in this subgroup. Therefore, the classification of esophageal motility disorders using HRM is crucial before choosing the modality of treatment in these patients.

Endoluminal functional lumen imaging probe (EndoFLIP) is emerging as a useful modality in establishing a diagnosis in cases with equivocal findings on high-resolution esophageal manometry. These cases include those with clinical and radiological findings compatible with achalasia but normal-appearing relaxation on manometry (integrated relaxation pressure < 15 mm Hg) and those with a manometric diagnosis of EGJOO.

Endoscopic Management Options

The endoscopic management of achalasia include botulinum toxin injection, PD, and POEM. Of these, botulinum toxin injection is reserved for elderly and frail patients, unsuitable for other durable treatment modalities like PD or myotomy.

Pneumatic Dilatation

PD has been the mainstay of endoscopic management for several decades now. With the availability of low-compliance pneumatic balloons and the graded protocol for dilatation, the outcomes of PD have improved substantially ( Fig. 1 ). Although the technique of PD with regard to the inflation pressure and duration of inflation has not been standardized, it does not seem to influence the results of dilatation. Nevertheless, accurate positioning of the balloon and disappearance of the waist are important during dilatation for optimal outcomes.

More recently, a hydraulic balloon dilatation device (EsoFLIP Crospn Ltd) has been utilized in cases with idiopathic achalasia. Using this system, dilation is achieved by injecting saline, assisted by electrohydraulic pump. This allows stepwise and controlled dilation. Since the catheter is connected to the EndoFLIP system, the diameter as well as cross-sectional area can be measured during dilatation. Although the results from initial studies appear encouraging, comparative studies are required with pneumatic dilatation before recommending hydraulic dilatation in routine practice.

Outcomes

The outcomes of PD are largely dependent on the protocol used, that is, single versus graded versus graded and on-demand dilatation ( Fig. 1 ). There is ample data to suggest that single dilatation does not provide durable response and majority (~ 70%) will require retreatment at 5 to 6 years follow-up. The current best practice is graded dilatation using larger balloons (30 mm, 35 mm, and 40 mm balloons). The most robust evidence regarding the efficacy of graded and on-demand dilatation was provided by the landmark European achalasia trial. In this randomized trial, graded dilatation was performed initially using 30 mm and 35 mm balloons in all the patients, followed by 40 mm in symptomatic patients. Subsequently, on-demand dilatation using 35- and 40-mm balloons was allowed in those with recurrence of symptoms. With this protocol, clinical success was achieved in 90% and 86% at 1 and 2-years follow-up, respectively. Although effective, nearly one-third of patients will experience symptom recurrence after initial series of graded dilatation during follow-up. In these cases, long-term remission can be achieved in approximately 70 to 90% of cases with repeated and on-demand dilatations.

Predictors of Outcomes

The preprocedure predictors for poor response to PD include young age (≤ 40 years), male gender, high-baseline LES pressure (> 50 mm Hg), dilated esophagus (> 3 cm) and type III achalasia. Postdilatation predictive factors for relapse after PD include incomplete barium emptying (< 50%) and postdilatation LES pressure > 10 mm Hg or < 50% reduction in the LES pressure. Of these, young age ( < 40 years) and

Fig. 1 Outcome of pneumatic dilatation according to the protocol (single vs graded vs graded plus on-demand dilatation).
type III achalasia have been shown to consistently affect the response to PD.\textsuperscript{19,20} Besides these, EndoFLIP is emerging as a novel tool in predicting the immediate outcomes of PD. An increase in EGI-distensibility index of 1.8 mm\textsuperscript{2}/mm Hg after a single PD predicts an immediate response with an accuracy of 87\%.\textsuperscript{21}

**Adverse Events**

Perforation (1–3\%) is the most dreaded complication of PD. Conservative management is suffice in a substantial proportion of cases, suggesting that the requirement for surgery is not universal.\textsuperscript{22,23} The most important risk factor for perforation is initial dilatation with a 35-mm balloon.\textsuperscript{8} In a systematic review (including 10 studies, 643 patients), the rate of perforations was higher when 35-mm balloon was used for initial dilatations (9.3\% vs. 0.97\%, \textit{p} = 0.0017).\textsuperscript{8} In addition, the risk may be higher in elderly cases (> 65 years).\textsuperscript{22} Therefore, initial dilatations should be performed using a 30-mm balloon, especially in elderly patients. The guidelines by European Society of Gastroenterology (ESGE) recommend dilatation with a 30-mm, followed by a 35-mm balloon at a planned interval of 2 to 4 weeks, with a subsequent 40-mm dilation when there is insufficient relief.\textsuperscript{7}

**Myotomy: Heller’s and Endoscopic**

**Laparoscopic Heller’s Myotomy**
Heller’s myotomy was introduced by Sir Ernst Heller in 1914. Initially, Heller’s myotomy was performed via laparotomy and not accompanied by a fundoplication wrap. Over a century old, the procedure of Heller’s myotomy has undergone several modifications. As of now, the procedure is performed laparoscopically and combined with anterior (Dor) or posterior (Toupet) fundoplication. In the current form, Heller’s myotomy is not only less invasive but also associated with less postoperative reflux.\textsuperscript{24}

**Outcomes**
The safety and efficacy of Heller’s myotomy has been established in multiple studies. The short- to midterm clinical success with Heller’s myotomy ranges from 80 to 90\% at a follow-up of ≤ 5 years, whereas symptom remission beyond 10 to 15 years is seen in 70 to 80\% of patients.\textsuperscript{25–27} The notable reasons of failure or symptom relapse after Heller’s myotomy include incomplete myotomy, reflux, fibrosis, fundoplication failure, and progression of the disease. Majority of the failures occur within 12 months of surgery, presumably due to incomplete myotomy.\textsuperscript{28} The management options in these cases include relaparoscopic myotomy, PD, and POEM with success rates of 64 to 79\%, 57 to 89\%, and 80 to 95\%, respectively.\textsuperscript{29} However, complications may be higher in re-Heller’s myotomy than in primary surgery of achalasia, with a conversion rate to open surgery of 6\%.\textsuperscript{29}

**Predictors of Outcomes**
The predictors for early dysphagia after Heller’s myotomy include preoperative dilatation, fundoplication, and botulinum toxin injection.\textsuperscript{30} Other reported predictors for negative outcomes after surgical myotomy include presence of chest pain, severe preoperative dysphagia, sigmoid esophagus, baseline LES pressure < 30 mm Hg, and type III achalasia.\textsuperscript{20,28,31–33} The predictors for good response include manometric type II achalasia, high-baseline LES pressure (> 30 mm Hg), and extended myotomy toward gastric side (3 cm).\textsuperscript{28,32,34}

**Adverse Events**
The most important intraoperative complication of Heller’s myotomy is esophageal or gastric perforation with a cumulative incidence of approximately 7\%.\textsuperscript{35} Majority of the perforations are recognized and repaired intraoperatively with minimal postoperative consequences. GERD is the most frequent delayed adverse event and occurs in about one-third of patients after LHM without fundoplication.\textsuperscript{35} With the addition of partial fundoplication procedure (Dor or Toupet), GERD is noticed in 8 to 10\% of patients during short-term follow-up.\textsuperscript{24,35} However, there is some evidence that the incidence of GERD increases with increasing follow-up, highlighting the need for regular objective assessment in these patients.\textsuperscript{25,26}

**Peroral Endoscopic Myotomy**
POEM is the most recent addition to the treatment modalities for achalasia cardia. The seminal works by Sumiyama and Pasricha in animal models are credited for the introduction of POEM and other procedures, listed under the umbrella of third space endoscopy.\textsuperscript{36,37}

**Outcomes**
Since its introduction nearly a decade ago, multiple studies have established the safety and efficacy of POEM in achalasia. In major studies, the efficacy of POEM is > 90\% at 1 to 2 years follow-up.\textsuperscript{38–40} Emerging data suggests that the response to POEM may be durable at midterm follow-up. Clinical success at ≥ 4 years follow-up has been recorded in 80 to 95\% patients.\textsuperscript{41–46} POEM has also shown to be effective in cases with symptom relapse after PD and Heller’s myotomy.\textsuperscript{47} The response rate ranges from 80 to 95\% in cases with prior Heller’s myotomy at a follow-up ranging from 8.5 to 28 months.\textsuperscript{48–50} In a recent systematic review (9 studies, 272 patients), the pooled clinical success after POEM was 90\% (95% CI 83.1–96.8\%).\textsuperscript{51} Considering its excellent safety and efficacy, recent guidelines published by prominent gastrointestinal (GI) societies have included POEM in the management protocol for achalasia.\textsuperscript{52–55}

The management in cases with relapse of symptoms after POEM has not been studied well. Limited data suggests that re-POEM may provide the best outcomes in these cases.\textsuperscript{56–58} A recent multicenter study evaluated the response to various treatments in 99 patients who experienced recurrence of symptoms after POEM.\textsuperscript{58} Clinical success was highest in cases who underwent re-POEM (76\%), followed by PD (60\%) and Heller’s myotomy (29\%). In contrast, the response to PD was particularly poor (0–20\%) as compared with POEM (63\%) and Heller’s myotomy (45\%) in this setting in another study.\textsuperscript{57}
Predictors of Outcomes
There is paucity of studies evaluating the risk factors for poor response after POEM. The available data suggests that the probability of clinical failure is higher in those with pretreatment Eckardt score ≥ 9, previous treatment, intra procedural mucosal injury, reflux, and esophageal dilatation (≥ grade II or ≥ 3.5 cm).60-61 The Eckardt score is a symptom-based score (0–3), regurgitation (0–3), chest pain (0–3) and weight loss (0–3), whereas esophageal dilatation is graded as grade I (< 3.5 cm), grade II (≥ 3.5–6 cm) and grade III (> 6 cm). In two recent studies, risk-scoring systems were devised using these risk factors to predict clinical failure after POEM. These scoring systems need to be validated in future studies to confirm their utility in routine clinical practice.

EndoFLIP is a novel tool that uses impedance planimetry to assess the dynamics of GEJ, including diameter, volume and pressure changes. The information provided by EndoFLIP can be used to aid in the diagnosis of achalasia as well as to determine the adequacy of myotomy and predict outcomes after treatment. Intraoperative FLIP during POEM has been shown to correlate with treatment outcomes as well as postoperative reflux. In this regard, intraoperative EGJ-cross-sectional area and distensibility index appear to be useful parameters in assessing the response to POEM.62-65

Adverse Events
Major adverse events are uncommon with POEM and occur in 1 to 3% patients.66 Insufflation-related events like subcutaneous emphysema and pneumoperitoneum are common but rarely clinically significant. Mucosal injuries and delayed mucosal barrier failure are the most important clinically relevant group of adverse events. Consequently, oral contrast studies are commonly performed before initiating oral feeds after POEM, although their utility remains questionable in this setting.67

Gastroesophageal reflux disease (GERD) is the most common delayed adverse event after POEM. Nearly half of the patients have evidence of GERD on 24-hour pH study, and reflux esophagitis is noticed in 20 to 40% of patients at 3 to 12 months after POEM. However, majority of the patients are asymptomatic for GERD, develop mild esophagitis (Los Angeles grade A or B) and respond well to proton-pump inhibitor (PPI) therapy. There are no predictive factors consistently shown to influence the rate of GERD after POEM. Low-integrated relaxation pressure after POEM, female gender, division of oblique fibers during posterior myotomy, excess myotomy along gastric side (≥ 2–2.5 cm), presence of hiatus hernia, and full thickness myotomy have been shown to be associated with an increased incidence of GERD after POEM in few studies. It is important to note that the literature is heterogenous with regard to the predisposing factors for GERD after POEM. Therefore, quality studies are required to confirm and validate the conclusions drawn by these studies.

Several modifications in the technique of POEM have been proposed to reduce the incidence of GERD after POEM. These include preservation of oblique fibers during posterior POEM, addition of fundoplication during anterior POEM, and avoiding excess gastric myotomy (≥ 3 cm). However, in the absence of quality data, it may be premature to conclude the efficacy of these strategies.

Pneumatic Dilatation versus Myotomy (POEM and Heller’s)
Graded PD, Heller’s myotomy and, more recently, POEM constitute the mainstay of management in achalasia cardia. PD and Heller’s myotomy have been compared in multiple quality randomized trials (Table 1). Overall, the results suggest

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>N</th>
<th>Clinical success</th>
<th>Adverse events</th>
<th>Follow-up (years)</th>
<th>Reflux esophagitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boeckxstaens et al62</td>
<td>RCT</td>
<td>PD 95 LHM 106</td>
<td>86% 90%</td>
<td>4% 12%</td>
<td>2</td>
<td>19% 21%</td>
</tr>
<tr>
<td>Moonen et al44</td>
<td>RCT</td>
<td>PD 96 LHM 105</td>
<td>82% 84%</td>
<td>5% 11%</td>
<td>≥ 5</td>
<td>14% 18%</td>
</tr>
<tr>
<td>Meng et al66</td>
<td>R</td>
<td>PD 40 POEM 32</td>
<td>60% 93%</td>
<td>No major AE</td>
<td>3</td>
<td>NR</td>
</tr>
<tr>
<td>Zheng et al68</td>
<td>R</td>
<td>PD 26 POEM 40</td>
<td>57.5% 92.3%</td>
<td>No major AE</td>
<td>1</td>
<td>NR</td>
</tr>
<tr>
<td>Ponds et al70</td>
<td>RCT</td>
<td>PD 66 POEM 64</td>
<td>54% 92%</td>
<td>3% 0%</td>
<td>2</td>
<td>7% 41%</td>
</tr>
<tr>
<td>Kim et al72</td>
<td>R</td>
<td>PD 177 PD 66</td>
<td>68% 91.8%</td>
<td>1.7% 3.1%</td>
<td>2</td>
<td>0.6% 6.3%</td>
</tr>
<tr>
<td>Harvey et al75</td>
<td>R</td>
<td>PD 4748 HM 2190</td>
<td>86.2% 81.9%</td>
<td>3.8% 2.6%</td>
<td>10</td>
<td>NR</td>
</tr>
</tbody>
</table>

Abbreviations: LHM, laparoscopic Heller’s myotomy; NR, not reported; P, prospective; PD, pneumatic dilatation; POEM, per-oral endoscopic myotomy; R, retrospective; RCT, randomized controlled trial.

* 30-day emergency readmission.
Table 2  Outcomes of endoscopic versus surgical myotomy in achalasia cardia

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>N</th>
<th>Clinical success</th>
<th>Adverse events</th>
<th>Follow-up</th>
<th>Reflux esophagitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bhayani et al⁴¹</td>
<td>P</td>
<td>HM 64</td>
<td>Dysphagia to solids 29% vs 0%</td>
<td>17.1% 10.8% (mucosal injuries)</td>
<td>6 m</td>
<td>NR</td>
</tr>
<tr>
<td>Kumagai⁴²</td>
<td>P</td>
<td>HM 41</td>
<td>NR 90%</td>
<td>4.9% 2.4%</td>
<td>12 m</td>
<td>NR</td>
</tr>
<tr>
<td>Kumbhari et al⁴⁰</td>
<td>R</td>
<td>LHM 26</td>
<td>80.8% 98%</td>
<td>27% 6%</td>
<td>8.6 m</td>
<td>21.5 m</td>
</tr>
<tr>
<td>Chan et al⁴³</td>
<td>R</td>
<td>LHM 23</td>
<td>13% 0% (1%)</td>
<td>NR</td>
<td>60 m</td>
<td>6 m</td>
</tr>
<tr>
<td>Schneider et al⁴⁴</td>
<td>R</td>
<td>LHM 25</td>
<td>84% 91%</td>
<td>3 7³ ³⁶ weeks</td>
<td>158 weeks</td>
<td>31.6% 53.4%</td>
</tr>
<tr>
<td>Hanna et al⁴⁶</td>
<td>R</td>
<td>LHM 54</td>
<td>59% 74%</td>
<td>NR</td>
<td>37 m</td>
<td>22 m</td>
</tr>
<tr>
<td>Shea et al⁴⁷</td>
<td>P</td>
<td>HM 97</td>
<td>65% 73.3%</td>
<td>NR</td>
<td>45 m</td>
<td>18.2 m</td>
</tr>
<tr>
<td>Wirsching et al⁴⁸</td>
<td>R</td>
<td>LHM 28</td>
<td>13.6% 11.1%</td>
<td>14.2% 8.8%</td>
<td>102 d</td>
<td>83 d</td>
</tr>
<tr>
<td>Werner et al⁴⁹</td>
<td>R</td>
<td>LHM 109</td>
<td>81.7% 83%</td>
<td>7.8% 2.7%</td>
<td>24 m</td>
<td>29% 44%</td>
</tr>
<tr>
<td>Constantini et al⁵⁰</td>
<td>R</td>
<td>LHM 54</td>
<td>97.7% 99.3%</td>
<td>2.1% 5%</td>
<td>31 m</td>
<td>24 m</td>
</tr>
<tr>
<td>Podboy et al⁵¹</td>
<td>R</td>
<td>LHM 43</td>
<td>65.1% 72.7%</td>
<td>20.9% 12.7%</td>
<td>5.4 years</td>
<td>3.9 years 4.7% 1.8%</td>
</tr>
</tbody>
</table>

Abbreviations: LHM, laparoscopic Heller’s myotomy; NR, not reported; P, prospective; POEM, peroral endoscopic myotomy; R, retrospective; RCT, randomized controlled trial.

² Recurrent dysphagia.
³ Mucosal injuries (actual numbers).

Table 3  Comparison of the currently available endoscopic modalities for achalasia cardia

<table>
<thead>
<tr>
<th></th>
<th>Pneumatic dilatation (multiple sessions)</th>
<th>Peroral endoscopic myotomy</th>
<th>Heller’s myotomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy: short term</td>
<td>90% (1-year) 54–86% (2 years)</td>
<td>&gt; 90% (1–3 years)</td>
<td>93% (1-year) 90% (2-year)</td>
</tr>
<tr>
<td>Efficacy: long-term</td>
<td>78–93% (≥ 4–5 years)</td>
<td>80–95% (≥ 4 years)</td>
<td>84% (5 years) 70–80% (≥ 10 years)</td>
</tr>
<tr>
<td>Predictors of poor outcomes</td>
<td>Young age (≤ 40 years), type III achalasia, high LES pressure &gt; 50 mm Hg</td>
<td>Prior treatment, mucosal injury, reflux, sigmoid esophagus, dilated esophagus (≥ 3.5 cm), high baseline Eckardt score</td>
<td>Presence of chest pain, severe preoperative dysphagia, sigmoid esophagus, resting LES pressure &lt; 30 mm Hg, type III achalasia</td>
</tr>
<tr>
<td>Complications</td>
<td>Perforation (1–3%), bleeding (2%), GERD (9%)</td>
<td>Mucosal injuries (2–4%), delayed bleeding (&lt; 1%)</td>
<td>Perforation (7%)</td>
</tr>
<tr>
<td>Indications</td>
<td>Type I and II achalasia preferably &gt; 40 years, relapse after POEM or Heller’s myotomy</td>
<td>All subtypes of achalasia especially type III achalasia, relapse of symptoms after PD or Heller’s myotomy</td>
<td>All subtypes of achalasia, relapse after PD or POEM</td>
</tr>
<tr>
<td>Advantages</td>
<td>Effective in type I and II achalasia, widely available, cost effective</td>
<td>Durable response, effective in all subtypes of achalasia, more effective than PD and HM in type III achalasia</td>
<td>Durable response, effective in all subtypes of achalasia, less postoperative GERD compared with POEM</td>
</tr>
<tr>
<td>Disadvantages</td>
<td>Multiple interventions required, relatively ineffective in young (≤ 40 years) and those with type III achalasia</td>
<td>High incidence of GERD, need of expertise</td>
<td>Probably inferior to POEM in type III achalasia, GERD increases with follow-up</td>
</tr>
</tbody>
</table>

Abbreviations: GERD, gastroesophageal reflux disease; HM, Heller’s myotomy; LES, lower esophageal sphincter; PD, pneumatic dilatation.
that these two modalities are comparable with respect to short- and long-term outcomes.12,14 On the other hand, a single series of dilatation may not provide durable response and, therefore, regarded as inferior to Heller’s myotomy. The protocol of dilatation utilized in the landmark European achalasia trial, that is, graded and on-demand, has been widely accepted as the standard of care in cases undergoing PD. With this protocol, the clinical success at 2 years (86% vs. 90%) and ≥ 5 years (84% vs. 82%) were comparable in PD and Heller’s myotomy groups, respectively.12 The results of this study were further substantiated by a large nationwide cohort study, including 6938 subjects, where PD and Heller’s myotomy had similar efficacy over 10-years follow-up (86% vs. 82%).25

POEM has been compared with PD in several cohort studies majority of which conclude that POEM is superior to PD (Table 1).76-78 However, the important shortcomings of these trials include retrospective design, suboptimal protocol of PD, and difference in the duration of follow-up. More recently, two high quality randomized trials compared POEM to PD and Heller’s myotomy.79,80 In the multicenter randomized trial by Ponds et al, clinical success with POEM was superior to PD at 2-years follow-up (92% vs. 54%, p < 0.001).79 However, GERD (reflux esophagitis) was more in the POEM group (41% vs. 7%; p = 0.002).

Endoscopic and surgical myotomy appear comparable with regard to efficacy at least in short-term follow-up (Table 2).81-89 In the randomized study by Werner and colleagues, POEM was noninferior to laparoscopic Heller’s myotomy with Dor’s fundoplication at 2 years (83% vs. 81.7%). However, the downside of POEM was a higher incidence of reflux esophagitis (44% vs. 29%).80

POEM may be superior to Heller’s myotomy in cases with type III achalasia and other nonachalasia spastic esophageal motility disorders like hypercontractile esophagus and distal esophageal spasm.89,90 In a retrospective cohort study, the clinical success after POEM was significantly better than Heller’s myotomy in selected cases with type III achalasia.90 Subsequent studies have also confirmed excellent outcomes with POEM in spastic motility disorders of esophagus.91-99 The ability to perform long esophageal

Table 4 Guidelines and recommendations for the endoscopic management of achalasia cardia

<table>
<thead>
<tr>
<th></th>
<th>ESGE13</th>
<th>ASGE14</th>
<th>ACG15</th>
</tr>
</thead>
</table>
| Botulinum toxin inj. | • Safe and effective  
• Indicated in patients unfit for more invasive treatments, or in whom a more definite treatment needs to be deferreda | • Should be avoided as definitive therapy for achalasia patientsb  
• Should be reserved for patients who are not candidates for other definitive therapiesb | • First-line therapy for patients with achalasia that are unfit for definitive therapiesb  
• BTX injection does not significantly affect performance and outcomes of myotomyb |
| Pneumatic dilatation | Graded PD is safe and efficacious treatment for achalasiaa | • PD is an effective modality for achalasiaa  
• PD is preferred over BTX injection for patients with achalasiaa | • PD is superior to medical therapy in relieving symptoms and physiologic parameters of esophageal emptyinga  
• PD is superior to medical therapy in relieving symptoms and physiologic parameters of esophageal emptyinga |
| Laparoscopic Heller’s myotomy | • LHM combined with an antireflux procedure is an effective and relatively safe therapy for achalasiaa  
• LHM, graded repetitive pneumatic dilatation, and POEM have comparable efficacya  
• Recurrent or persistent dysphagia after LHM should be managed with PD, POEM or redo surgeryc | • LHM, PD and POEM are effective and comparable therapeutic modalities for patients with type I and II achalasiaa | • Myotomy with fundoplication is superior to myotomy without fundoplication in controlling distal esophageal acid exposurea  
• Dor or Toupet fundoplication is recommended to control esophageal acid exposurea |
| Peroral endoscopic myotomy | POEM is a safe and efficacious treatment for achalasiaa | • POEM is an effective modality for achalasiaa  
• POEM should be preferred in type III achalasiaa  
• POEM and LHM are comparable for type I and II achalasiaa | • Tailored POEM or LHM preferred over dilatation for type III achalasiaa  
• POEM would be a better treatment option in those with type III achalasia,  
• POEM is associated with a higher incidence of GERD as compared with LHM with fundoplication and PDc  
• POEM, PD and LHM are comparable in type I and II achalasiaa |

Abbreviations: BTX, botulinum toxin; LHM, laparoscopic Heller’s myotomy; PD, pneumatic dilatation; POEM, peroral endoscopic myotomy.

very low evidence.

low evidence.

moderate evidence.

high evidence.
myotomies explains the superior response with POEM in these cases. A recent meta-analysis described the clinical outcomes after Heller’s myotomy and POEM for achalasia based on manometric subtypes. POEM was superior to Heller’s myotomy for type I (95% vs. 81%) and III (93% vs. 71%) achalasia. The recent guidelines by the American Society for Gastrointestinal Endoscopy (ASGE) and the American College of Gastroenterology (ACG) recommend POEM for type III achalasia (very low quality evidence). Other reported advantages of POEM over Heller’s myotomy include shorter procedure time, less postoperative pain, and shorter hospitalization.

Individualized Management of Achalasia: Putting it all Together

Currently, there are three effective modalities available for the management of achalasia, including PD, POEM, and Heller’s myotomy (►Table 3). The choice among these modalities is based on several factors which include availability and expertise, presence of risk factors of poor response with a particular modality, and patient’s preferences (►Fig. 2). The major gastroenterology societies have published the updated guidelines regarding the management of achalasia and allied disorders. The salient features of these guidelines have been summarized in ►Table 4.

The pros and cons of each procedure should be detailed to the patients for a shared decision-making. PD is widely available, safe, cost-effective and provides durable response in appropriately selected patients. The patients should be aware regarding the requirement of repeated interventions and a small risk of perforation associated with PD. In cases with presumed poor response to PD (age < 40 years, type III achalasia, high LES pressure > 50 mm Hg), endoscopic or surgical myotomy is preferable. Endoscopic and surgical myotomy are similarly effective across all age groups and subtypes of achalasia, except in cases with type III achalasia, where POEM may be more effective than Heller’s myotomy. The important limitations with endoscopic myotomy are lack of data on long-term efficacy, that is, beyond 10 years and high incidence of postoperative GERD. Therefore, the long-term need for antireflux medications should be explained. In cases with relapse of symptoms after myotomy (POEM or Heller’s), PD may be a reasonable first-line treatment with acceptable results, especially after failed Heller’s myotomy. Alternatively, remyotomy, especially POEM, may be performed with superior outcomes as compared with re-Heller’s myotomy, although the data is limited (►Fig. 3).

Abbreviations

POEM per-oral endoscopic myotomy
ACG American College of Gastroenterology
ASGE American Society of Gastrointestinal Endoscopy
ESGE European Society of Gastrointestinal Endoscopy
GEJ gastroesophageal junction
GERD gastroesophageal reflux disease
HRM high resolution manometry
LES lower esophageal sphincter
PD pneumatic dilatation

Funding

The authors (Z.N., M.R., D.N.R) received no funding or support for this manuscript.

Conflict of Interest

All the authors declare no conflict of interest.

Acknowledgments

None.

References

8 van Hooij FB, Prins LJ, Snout AJPM, Bredenoord AJ. Efficacy and safety of pneumatic dilation in achalasia: A systematic review and meta-analysis. Neurogastroenterol Motil 2019;31(7):e13548
42 Li QL, Wu QN, Zhang XC, et al. Outcomes of per-oral endoscopic myotomy for treatment of esophageal achalasia with a median
follow-up of 49 months. Gastrointest Endosc 2018;87(6):1405–1412.e3, e3


55 Vaezi MF, Pandolfino JE, Yadlapati RH, Greer KB, Kavitt RT. AGC Clinical Guidelines: Diagnosis and Management of Achalasia. Am J Gastroenterol 2020;115(9):1393–1411


patients with achalasia: a randomized clinical trial. JAMA 2019;322(2):134–144
97 Kane ED, Budhraja V, Desilets DJ, Romanelli JR. Myotomy length informed by high-resolution esophageal manometry (HREM) results in improved per-oral endoscopic myotomy (POEM) outcomes for type III achalasia. Surg Endosc 2019;33(3):886–894